GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - XENON PHARMACEUTICALS INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex) provided for any period.
• Explicit timeline for commercial launch: Expected to begin beginning of 2028 (approx. Q1 2028), contingent on FDA approval in the "upcoming months" following the September NDA filing and subsequent 3-month DEA scheduling.
• Capital runway: $1.2 billion in cash and cash equivalents sufficient to fund operations through 2029.

Business-Segment Outlook:

• Focal Seizures (Zetucalner):
  • Label Strategy: Initial launch targeting refractory late-line patients (patients on 2-3 anti-seizure meds) seen by epileptologists; planned strategic expansion over time to first-add-on patients (earlier-line treatment) via a new Phase 3B study (X-First) launching enrollment in H1 2028.
  • Target Audience: Initial phase targets 5,000–6,000 physicians (2,400 epileptologists + high-prescribing general neurologists + advanced practice providers); long-term goal to broaden to the 18,000 general neurologists in the US.
  • Dosing: Four doses on label (including low-dose options like 10-15mg) to allow flexibility for BMI and AE management without titration requirements.
• Neuropsychiatry:
  • MDD (Exonova 2): Readout accelerated to December 2027 (previously Q1 2027) after voluntary pause of enrollment in Exonova 3; results will inform dose escalation schema for potential re-initiation.
  • Bipolar Depression: Enrollment paused pending MDD readout; timeline to resume uncertain.
  • MDD (Exonova 3): Enrollment paused to address observed neuropsychiatric adverse events not seen in Phase 2b; potential for protocol amendment (dose modifications) rather than program termination depending on Exonova 2 data.
• Pain Programs:
  • Targets: Three programs in clinic (2x NAV 1.7, 1x KV7); targeting acute pain for Phase 2 Proof of Concept (POC) in H1 2028 with a strategic pivot toward chronic pain.
  • Combinations: Potential for combinations of NAV 1.7 and KV7 or with other targets (e.g., Vertex's approach) to achieve broader analgesic effects.

Market and Competitive Outlook:

• Commercial Model: Adoption of a Specialty Pharmacy (SP) model rather than retail distribution to mitigate high abandonment rates, manage prior authorizations, and improve patient connectivity; aims to shift the typical "low and slow" epilepsy launch curve to the left.
• Market Share/Adoption: Anticipated to replace generic-heavy landscape (only one branded competitor, Sinobamate/Xcopri, last launched in 2019); positioning as the first potassium channel modulator in the US if approved.
• Access: Projected payer mix at launch: 40% Commercial, 40% Medicaid (higher prevalence due to employment challenges for patients), and 20% Medicare; leveraging "protected class" status of epilepsy for government payers.

Macro / Industry Outlook:

• Industry Trends: Observes industry shift from rare disease SP models to larger patient populations over the last 5–10 years; notes retail channel incentives favor generics, creating a barrier for specialty new drugs.
• Regulatory Environment: Anticipates standard DEA scheduling timeline of 3 months post-FDA approval; no specific macroeconomic headwinds (rates, FX, tariffs) discussed affecting the outlook.

Strategic Initiatives:

• Launch Execution: Building a commercial leadership team with experience from large and small biotech firms; finalizing go-to-market strategy, demand studies, and pricing research pre-approval.
• Clinical Development:
  • Phase 3B (X-First): Enrolling first-add-on patients in H1 2028; data presentation anticipated at AES meeting in December 2027 (Denver).
  • Data Releases: Upcoming presentation of 60-month XTOL OLE data at AES; published Phase 3 data in JAMA Neurology (already released).
  • Early Stage: Advancing pain programs to Phase 2 POC in H1 2028.
• Capacity: No new manufacturing capacity announcements; focus is on commercial infrastructure scaling.

Risks and Headwinds to Outlook:

• Regulatory Timing: Delay in FDA approval or unexpected DEA scheduling could push launch beyond beginning of 2028.
• Clinical Safety: Neuropsychiatric adverse events observed in MDD trials could necessitate further dose modifications, delay re-initiation of trials, or halt the MDD/Bipolar programs entirely.
• Commercial Uptake: Potential slower adoption by general neurologists compared to epileptologists; risk of the "low and slow" uptake pattern typical of new anti-seizure medications if differentiation is not clear.
• Market Dynamics: High generic competition and potential payer resistance despite epilepsy's protected class status; reliance on successful navigation of prior authorization hurdles.

Management Tone on the Future:

• Confidence Level: High confidence in the commercial potential of Zetucalner, citing its novel mechanism, lack of drug-drug interactions, and lack of need for titration.
• Hedges/Qualifiers: Management describes the MDD indication as "hard" and remains "sanguine" but hopeful; acknowledges uncertainty in the final timeline for MDD re-initiation pending Dec 2027 data.
• Strategic Shift: Explicit pivot from a "rare disease" mindset to a "large opportunity" in focal seizures and chronic pain, emphasizing scalability and broad physician adoption.

Miscellaneous:

• Conference Presence: Announced largest-ever presence at the American Epilepsy Society (AES) meeting in December 2027, focusing on disease state awareness and physician recruitment for the X-First study.
• Pipeline Depth: Continues to maintain an active research program for NAV 1.1 (Dravet syndrome) and a partner program with Neurocrin (NAV 1.2, 1.6).